The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2023 | Analyzing isatuximab in quadruplet combinations in transplant-ineligible multiple myeloma
Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, gives an update on a Phase Ib study (NCT02513186) in which isatuximab was analyzed in combination with bortezomib, cyclophosphamide and dexamethasone (VCD) and in combination with bortezomib, lenalidomide and dexamethasone (VRD) in newly diagnosed, transplant-ineligible multiple myeloma. Dr Ocio shares some results from this study and further comments on where this combination may fit in the myeloma treatment armamentarium. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
